



(86) Date de dépôt PCT/PCT Filing Date: 2014/01/24
(87) Date publication PCT/PCT Publication Date: 2014/08/14
(85) Entrée phase nationale/National Entry: 2015/07/29
(86) N° demande PCT/PCT Application No.: US 2014/012854
(87) N° publication PCT/PCT Publication No.: 2014/123703
(30) Priorité/Priority: 2013/02/06 (US61/761,298)

(51) Cl.Int./Int.Cl. *A61L 27/36* (2006.01)
(71) Demandeur/Applicant:
LIFECCELL CORPORATION, US
(72) Inventeurs/Inventors:
MONTEIRO, GARY, US;
WAGNER, CHRISTOPHER T., US;
RODRIGUEZ, NEIL L., US;
DELOSSANTOS, AUBREY IRENE, US
(74) Agent: BORDEN LADNER GERVAIS LLP

(54) Titre : PROCÉDES POUR MODIFICATION LOCALISÉE DE PRODUITS DE TISSU
(54) Title: METHODS FOR LOCALIZED MODIFICATION OF TISSUE PRODUCTS

(57) **Abrégé/Abstract:**

Methods for treating tissue matrices and tissue matrices produced according to the methods are provided. The methods can include treating select portions of a tissue matrix with a cross-linking agent and/or a proteolytic enzyme to produce a tissue matrix with variable mechanical and/or biological properties.



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



WIPO | PCT



(10) International Publication Number

WO 2014/123703 A1

(43) International Publication Date
14 August 2014 (14.08.2014)

(51) International Patent Classification:

A61L 27/36 (2006.01)

(21) International Application Number:

PCT/US2014/012854

(22) International Filing Date:

24 January 2014 (24.01.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/761,298 6 February 2013 (06.02.2013) US

(71) Applicant: LIFECCELL CORPORATION [US/US]; One
Millennium Way, Branchburg, NJ 08876 (US).

(72) Inventors: MONTEIRO, Gary; 1113 Vanarsdale Drive,
Branchburg, NJ 08853 (US). WAGNER, Christopher, T.;
14 Nevius Drive, Flemington, NJ 08822 (US). RODRIG-
UEZ, Neil, L.; 30-8 Farm Road, Hillsborough, NJ 08844
(US). DELOSSANTOS, Aubrey, Irene; 538 East Main
Street, Bridgewater, NJ 08807 (US).

(74) Agents: VAN EMAN, Matthew, R. et al.; McCarter &
English, LLP, 265 Franklin Street, Boston, MA 02110
(US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,

HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(54) Title: METHODS FOR LOCALIZED MODIFICATION OF TISSUE PRODUCTS

(57) Abstract: Methods for treating tissue matrices and tissue matrices produced according to the methods are provided. The methods can include treating select portions of a tissue matrix with a cross-linking agent and/or a proteolytic enzyme to produce a tissue matrix with variable mechanical and/or biological properties.



WO 2014/123703 A1

METHODS FOR LOCALIZED MODIFICATION OF TISSUE PRODUCTS

[0001] This application claims priority under 35 U.S.C. § 119 to United States Provisional Patent Application 61/761,298, which was filed on February 6, 2013, and which is incorporated by reference in its entirety.

[0002] The present disclosure relates to tissue matrices, and more particularly, to methods for localized modification of mechanical and/or biological properties of tissue matrices.

[0003] Various tissue-derived products are used to regenerate, repair, or otherwise treat diseased or damaged tissues and organs. Such products can include intact tissue grafts and/or acellular or reconstituted acellular tissues (e.g., acellular tissue matrices from skin, intestine, or other tissues, with or without cell seeding). Such products generally have mechanical properties determined by the tissue source (i.e., tissue type and animal from which it originated) and the processing parameters used to produce the tissue products. Since tissue products are often used for surgical applications and/or tissue replacement or augmentation, the mechanical and biological properties of the tissue products are important. For example, tissue products must be able to provide suitable mechanical support (e.g., to close a tissue defect), while allowing tissue in-growth and regeneration. In some cases, however, it may be desirable to modify the mechanical and/or biological properties of tissue products. Furthermore, in order to improve the performance of tissue products for specific applications, it may be desirable to produce tissue products that have variable mechanical and/or biological properties. Accordingly, the present disclosure provides devices and methods for localized modification of mechanical and/or biological properties of tissue products, including acellular tissue matrices.

SUMMARY

[0004] According to various embodiments, a method for treating a tissue matrix is provided. The method can comprise selecting a collagen-containing tissue matrix and cross-linking select portions of the tissue matrix to produce a tissue matrix having mechanical or biological properties that vary across the tissue matrix. In some embodiments, the tissue matrix is an acellular tissue matrix. In certain embodiments, the tissue matrix comprises a dermal tissue matrix. In other embodiments, the tissue matrix is derived from a tissue selected from fascia, pericardial tissue, dura, umbilical cord tissue, placental tissue, cardiac valve tissue, ligament tissue, tendon tissue, arterial tissue, venous tissue, neural connective tissue, urinary bladder tissue, ureter tissue, and intestinal tissue.

[0005] In some embodiments, the method comprises cross-linking select portions of the tissue matrix by applying a fluid containing a cross-linking agent to the select portions. In certain embodiments, applying a fluid containing a cross-linking agent to the select portions comprises providing a solid surface having one or more channels configured to allow fluid to flow therethrough; contacting the tissue matrix with the surface; and causing fluid containing a cross-linking agent to flow through the channels. In various embodiments, the one or more channels have at least one of a serpentine pattern, a web-like pattern, a circular pattern, a grid pattern, and a linear pattern. In various embodiments, the cross-linking agent comprises at least one of glutaraldehyde, 1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC), or genepin.

[0006] In various embodiments, a method for treating a tissue matrix is provided. The method can comprise selecting a collagen-containing tissue matrix and contacting select portions of the tissue matrix with a proteolytic enzyme to

produce a tissue matrix having mechanical properties that vary across the tissue matrix. In some embodiments, the tissue matrix comprises a dermal tissue matrix. In other embodiments, the tissue matrix is derived from a tissue selected from fascia, pericardial tissue, dura, umbilical cord tissue, placental tissue, cardiac valve tissue, ligament tissue, tendon tissue, arterial tissue, venous tissue, neural connective tissue, urinary bladder tissue, ureter tissue, and intestinal tissue.

[0007] In some embodiments, contacting select portions of the tissue matrix with a proteolytic enzyme comprises applying a fluid containing the proteolytic enzyme to the select portions. In some embodiments, contacting select portions of the tissue matrix with a proteolytic enzyme comprises providing a solid surface having one or more channels configured to allow fluid to flow therethrough; contacting the tissue matrix with the surface; and causing fluid containing the proteolytic enzyme to flow through the channels. In some embodiments, the one or more channels have at least one of a serpentine pattern, a web-like pattern, a circular pattern, a grid pattern and a linear pattern.

[0008] In certain embodiments, the enzyme is bromelain. In some embodiments, the enzyme is selected from bromelain, papain, ficin, actinidin, or combinations thereof.

[0009] In some embodiments, the method further includes treating the tissue matrix to removal at least some of the cells and cellular components from the tissue matrix. In some embodiments, the method includes removing all the cells and cellular components from the tissue matrix.

[0010] In various embodiments, tissue products produced according to any of the disclosed methods are provided.

[0011] In certain embodiments, a tissue product is provided. The tissue product can comprise an acellular tissue matrix derived from a collagen-containing tissue, wherein the tissue matrix comprises a flexible sheet, and wherein the tissue matrix comprises select regions of cross-linked or proteolytically digested material, and wherein the mechanical or biological properties of the tissue matrix vary across the flexible sheet.

DESCRIPTION OF THE DRAWINGS

[0012] Figs. 1A-1B illustrate a device for microfluidic modification of a tissue product, according to certain embodiments.

[0013] Fig. 2 illustrates a device for microfluidic modification of a tissue product, according to certain embodiments.

[0014] Fig. 3 illustrates an acellular tissue matrix that has been treated to provide localized modification of mechanical and/or biological properties, according to certain embodiments.

[0015] Fig. 4 illustrates an acellular tissue matrix that has been treated to provide localized modification of mechanical properties and/or biological properties, according to certain embodiments.

[0016] Fig. 5 illustrates an acellular tissue matrix that has been treated to provide localized modification of mechanical properties and/or biological properties, according to certain embodiments.

[0017] Fig. 6 illustrates an acellular tissue matrix that has been treated to provide localized modification of mechanical properties and/or biological properties, according to certain embodiments.

[0018] Fig. 7 illustrates an acellular tissue matrix that has been treated to provide localized modification of mechanical properties and/or biological properties, according to certain embodiments.

[0019] Fig. 8 illustrates an acellular tissue matrix that has been treated to provide localized modification of mechanical properties and/or biological properties, according to certain embodiments.

[0020] Fig. 9 illustrates an acellular tissue matrix that has been treated to provide localized modification of mechanical properties and/or biological properties, according to certain embodiments.

[0021] Fig. 10 illustrates an acellular tissue matrix that has been treated to provide localized modification of mechanical properties and/or biological properties, according to certain embodiments.

[0022] Fig. 11 illustrates an acellular tissue matrix that has been treated to provide localized modification of mechanical properties and/or biological properties, according to certain embodiments.

DESCRIPTION OF CERTAIN EXEMPLARY EMBODIMENTS

[0023] Reference will now be made in detail to certain exemplary embodiments according to the present disclosure, certain examples of which are illustrated in the accompanying drawings. Wherever possible, the same reference numbers will be used throughout the drawings to refer to the same or like parts.

[0024] In this application, the use of the singular includes the plural unless specifically stated otherwise. In this application, the use of “or” means “and/or” unless stated otherwise. Furthermore, the use of the term “including”, as well as other forms, such as “includes” and “included”, is not limiting. Any ranges described

herein will be understood to include the endpoints and all values between the endpoints.

[0025] The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described. All documents, or portions of documents, cited in this application, including but not limited to patents, patent applications, articles, books, and treatises, are hereby expressly incorporated by reference in their entirety for any purpose.

[0026] As used herein “tissue product” will refer to any human or animal tissue that contains extracellular matrix proteins. “Tissue products” can include acellular or partially decellularized tissue matrices, as well as decellularized tissue matrices that have been repopulated with exogenous cells.

[0027] Various human and animal tissues can be used to produce products for treating patients. For example, various tissue products are available for regeneration, repair, augmentation, reinforcement, and/or treatment of human tissues that have been damaged or lost due to various diseases and/or structural damage (e.g., from trauma, surgery, atrophy, and/or long-term wear and degeneration). Such products can include, for example, acellular tissue matrices, tissue allografts or xenografts, and/or reconstituted tissues (i.e., at least partially decellularized tissues that have been seeded with cells to produce viable materials).

[0028] For surgical applications, it is often desirable to produce tissue products that have certain mechanical properties. For example, the tissue product, which may include a sheet of material, should possess sufficient strength to withstand stresses during the intended use. Certain tissue products may be used to repair defects (e.g., hernias), to support surrounding tissues or implants (e.g., for breast augmentation and/or reconstruction), or to replace damaged or lost tissue

(e.g., after trauma or surgical resection). Whatever the particular use, the tissue product should have sufficient strength, elasticity, and/or other mechanical properties to function until tissue regeneration and/or repair occurs.

[0029] Some tissue products, however, may be functionally improved by altering the mechanical properties of the products. For example, a number of acellular tissue matrix products are available, and often, such tissue matrices are in the form of a flexible sheet of material that has substantially uniform mechanical and/or biological properties over its entire surface area. For some indications, however, it may be desirable to alter the mechanical and/or biological properties of such tissue matrices such that the properties vary across the material. For example, in some embodiments, it may be desirable to strengthen, stiffen, weaken, or make more pliable select regions of a tissue product to produce a product having variable mechanical properties. In addition, in some embodiments, it may be desirable to modify certain elastic or viscoelastic properties of a tissue matrix, including, for example, the resistance to stretching at low deformation levels (e.g., toe-region mechanics).

[0030] It may be desirable to treat select regions of the tissue products to control the rate of degradation, cell in-growth, and/or vascularization after implantation. It is known that cross-linking can increase the resistance of tissue matrices to degradation by inflammatory cells within the body, and such increased resistance can slow the rate of weakening after implantation. Accordingly, in some embodiments, it may be desirable to provide localized cross-linking to provide areas of the tissue matrix that maintain their ability to provide mechanical support to an implantation site for longer times after implantation, while simultaneously providing

sufficient tissue matrix mass to support normal tissue regeneration within uncross-linked portions of the tissue matrix.

[0031] The present disclosure provides methods for treating tissues to provide variable mechanical and/or biological properties along the length, width, or thickness of a tissue matrix. The disclosure also provides tissue products produced using the methods of treatments.

[0032] According to various embodiments, a method for treating a tissue matrix is provided. The method can comprise selecting a collagen-containing tissue matrix and cross-linking select portions of the tissue matrix to produce a tissue matrix having mechanical and/or biological properties that vary across the tissue matrix. In some embodiments, the tissue matrix is an acellular tissue matrix. In certain embodiments, the tissue matrix comprises a dermal tissue matrix.

[0033] In various embodiments, a method for treating a tissue matrix is provided. The method can comprise selecting a collagen-containing tissue matrix and contacting select portions of the tissue matrix with a proteolytic enzyme to produce a tissue matrix having mechanical properties that vary across the tissue matrix.

[0034] The tissue products according to the present disclosure can be selected to provide a variety of different biological and/or mechanical properties. For example, an acellular tissue matrix or other tissue product can be selected to allow tissue in-growth and remodeling to assist in regeneration of tissue normally found at the site where the matrix is implanted. For example, an acellular tissue matrix, when implanted on or into fascia or other soft tissue, may be selected to allow regeneration of the fascia or other soft tissue without excessive fibrosis or scar formation. In certain embodiments, the tissue product can be formed from ALLODERM® or

STRATTICE™ (LIFECCELL CORPORATION, Branchburg, NJ), which are human and porcine acellular dermal matrices respectively. Alternatively, other suitable acellular tissue matrices can be used, as described further below. The tissues can be selected from a variety of tissue sources including skin (dermis or whole skin), fascia, pericardial tissue, dura, umbilical cord tissue, placental tissue, cardiac valve tissue, ligament tissue, tendon tissue, arterial tissue, venous tissue, neural connective tissue, urinary bladder tissue, ureter tissue, and intestinal tissue. The methods described herein can be used to process any collagenous tissue type and for any tissue matrix product. For example, a number of biological scaffold materials are described by Badylak et al., and the methods of the present disclosure can be used to treat those or other tissue products known in the art. Badylak et al., "Extracellular Matrix as a Biological Scaffold Material: Structure and Function," *Acta Biomaterialia* (2008), doi:10.1016/j.actbio.2008.09.013.

[0035] In some cases, the tissue matrix can be provided as a decellularized tissue matrix. Suitable acellular tissue matrices are described further below. In other cases, the method can further include processing intact tissue to remove cells or other materials either before, after, or both before and after cross-linking or proteolytic treatment according to the present application. The tissues can be completely or partially decellularized to yield acellular tissue matrices or extracellular tissue materials to be used for patients. For example, various tissues, such as skin, intestine, bone, cartilage, nerve tissue (e.g., nerve fibers or dura), tendons, ligaments, or other tissues can be completely or partially decellularized to produce tissue products useful for patients. In some cases, these decellularized products can be used without addition of exogenous cellular materials (e.g., stem cells). In certain cases, these decellularized products can be seeded with cells from

autologous sources or other sources to facilitate treatment. Suitable processes for producing acellular tissue matrices are described below.

[0036] In certain embodiments, tissue matrices can be treated to provide localized variation in mechanical and/or biological properties by contacting the tissue matrices with one or more cross-linking agents and/or proteolytic enzymes.

Generally, the matrices can be treated by contacting selected portions of the tissue matrices with a fluid containing the agent or enzyme and under conditions (e.g., temperature and/or pH) and for a time sufficient to produce a desired degree of cross-linking and/or proteolysis.

[0037] The fluid containing cross-linking agents or enzymes can be applied to selected regions of the tissue matrix in a variety of ways. In certain embodiments, the fluid is made to flow in contact with the tissue matrix to permit contact with only those regions of the tissue matrix that are selected for modification. Figs. 1A-1B illustrate a device 10 for microfluidic modification of tissue products, according to certain embodiments. As shown in Fig. 1A, the device 10 can include a rigid body with a bottom surface 12 and top surface 14, as well as a number of channels 16. When in use, the device 10 can be placed with the bottom surface 12 and channels 16 facing downward towards a rigid surface 15 (Fig. 1B). A tissue matrix 19 can be placed between the bottom surface 12 and the rigid surface 15 with sufficient pressure to substantially prevent flow of fluid through the tissue matrix 19 other than at regions surrounded by the channels 16. The fluid containing cross-linking agents or enzymes can be made to flow through the channels 16 via entrance and exit fluid supply tubings 18, 20. In some embodiments, each channel 16 can be connected to an individual supply tubing 18, 20, or one or more of the channels can be connected to supply tubing via manifolds, as long as a desired degree of fluid flow is achieved.

[0038] The channels 16 can have a variety of shapes, sizes and configurations. In general, the channels 16 should be spaced far enough apart to allow a seal to form between channels when placed in contact with a tissue matrix. Further, suitable channel widths can range from 1 micron to 5 cm, and suitable channel heights can range from 1 micron to 2 mm. In addition, the channel edges should be rounded or blunted to prevent tissue damage.

[0039] A number of different cross-linking agents and/or enzymes can be used to treat the tissue matrices. For example, suitable cross-linking agents can include glutaraldehyde, EDC, genepin, aldehydes, and/or lysyl oxidase; and suitable enzymes can include sulfhydryl proteases such as bromelain. In addition, the enzymes can include bromelain, papain, ficin, actinidin, or combinations thereof. The enzymes and cross-linking agents can be purchased commercially; or enzymes can be extracted from fruit sources. For example, one source of bromelain is MCCORMICK MEAT TENDERIZER, but the enzymes can also be extracted from pineapple and/or purchased in a medical-grade formulation.

[0040] The enzymes can be contacted with the tissues to increase the pliability of the tissue without causing undesirable degradation in other mechanical and/or biological properties. For example, when a batch of materials is produced with or without the enzyme treatments discussed herein, the enzyme treatments will not produce an undesirable change in at least one of tensile strength, tear strength, suture strength, creep resistance, collagenase susceptibility, glycosaminoglycan content, lectin content, burst strength, thermal transition temperature, or combinations thereof. In some cases, an undesirable change is a statistically significant reduction any one of tensile strength, tear strength, suture strength, creep resistance, glycosaminoglycan content, lectin content, burst strength; an increase in

collagenase susceptibility; or a change (upward or downward) in thermal transition temperature (as measure using differential scanning calorimetry).

[0041] In some cases, the enzymes are selected such that they cause site-specific cleavage of proteins within the tissues. For example, it has been found that treatment of porcine dermal materials with bromelain does not cause further alterations in the matrix structure after a certain amount of treatment. Therefore, treatment of dermis with bromelain does not cause further change in the matrix with prolonged exposure or after extended periods of time.

[0042] In addition, the enzymes and cross-linking agents can be applied to the tissues in a variety of suitable solutions. For example, bromelain has been found to be effective when applied to tissues in normal saline, but other suitable buffers (e.g., PBS) can be used.

[0043] The device 10 used to contact the tissue matrix 19 with enzymes and/or cross-linking agents can have a variety of different configurations. For example, as described in further detail below with respect to Figs. 3-10, the tissue matrix 19 can be treated by cross-linking and/or treatment with proteolytic enzymes at a number of suitable locations to produce a pattern providing desired variations in mechanical and/or biological properties. Fig. 2 illustrates a device 10' for microfluidic modification of tissue products, according to certain embodiments. As shown, the device 10' again includes a rigid structure with channels 16'. In the embodiment of Fig. 2, however, the channels 16' have a shape or pattern that is different than that of Fig. 1, thereby allowing contact of the cross-linking agent or proteolytic enzyme to produce a modified tissue matrix with a different configuration. Furthermore, the device 10' has two openings 18' and 20', which provide passages for flow of fluid into and out of the channels 16', rather than having multiple separate openings 18, 20, as

with the device of Fig. 1. Any suitable number of openings may be used to provide adequate flow of fluid through channels 16, 16'

[0044] The methods of the present disclosure can be used to modify mechanical and/or biological properties in a number of different locations. Figs. 3-10 illustrate acellular tissue matrices that have been treated to provide localized modification of mechanical and/or biological properties, according to certain embodiments. In various embodiments, the tissue matrices can be treated to modify select regions of a sheet-like tissue matrix over regions having a serpentine pattern 32 (Fig. 3), a spiral pattern 42 (Fig. 4), linear patterns 52, 62 (Figs. 5 and 6), curved patterns 72 (Fig. 7), along linear or longitudinally aligned patterns 82 in a cylindrically wrapped sheet 80 (Fig. 8), in a circular pattern 92 (Fig. 9), in a web-like pattern 102 (Fig. 10), or in a grid pattern 110 (Fig. 11).

[0045] The specific pattern of the region selected for localized cross-linking or proteolytic treatment can be selected for a variety of reasons. It is known that cross-linking can increase the resistance of tissue matrices to degradation by inflammatory cells within the body, and such increased resistance can slow the rate of weakening after implantation. Excessive cross-linking, however, can have adverse effects on cell infiltration and regeneration of normal tissue within the tissue matrix. Accordingly, in some embodiments, it may be desirable to provide localized cross-linking to provide areas of the tissue matrix that maintain their ability to provide mechanical support to an implantation site for longer times after implantation, while simultaneously providing sufficient tissue matrix mass to support normal tissue regeneration within uncross-linked portions of the tissue matrix.

[0046] Localized protease treatment may be used for a variety of reasons. For example, localized protease treatment can allow production of differing strength

or other mechanical properties treating the tissue to make native stronger. In addition, production of tissue matrices with localized pliability may be to allow a surgeon to place tissue in small openings, including passing a tissue matrix through a laparoscopic incision or trocar. In addition, production of tissue with localized pliability can be beneficial to allow matching of compliances with natural tissues or to match anisotropic mechanical properties of tissues.

[0047] The specific pattern of localized treatment may be selected based on a desired implantation site or treatment method. For example, in various embodiments, the pattern may be selected to provide a treated tissue matrix having improved mechanical properties (e.g., higher yield strength) along dimensions that may be more likely to experience higher loads during use. For example, in the embodiments of Figs. 3-6 and 9-10, the pattern may be selected to increase the strength of the sheet of tissue matrix along one or more axes parallel to the sheet of tissue matrix. Similarly, Fig. 7 illustrates a sheet of tissue matrix 70 that can include an upper convex surface 74 and lower convex surface 76, which may be well-suited for use in supporting a breast implant after breast reconstruction or augmentation, and the matrix 70 can be treated along lines 72 selected to increase the strength or elastic modulus of the matrix in direction that may be most likely to fail during use. Similarly, Fig. 8 illustrates a cylindrically shaped matrix 80 having a treatment pattern 82 along lines parallel to an axis of the matrix 80. The cylindrically shaped matrix 80 may be used as a connective tissue replacement (e.g., for a ligament, tendon, or linea alba), and the pattern 82 can be selected to provide desired strength, flexibility, or elastic properties to mimic nature tissue sites and/or to minimize failure rates after implantation.

[0048] The concentration, flow-rate, and specific enzyme or chemical used for cross-linking or proteolysis can be selected for a variety of reasons. For example, in general, the specific concentration and flow rate/time of exposure is selected based on the desired degree of cross-linking or proteolysis. In addition, since different enzymes and/or cross-linking agents may have proteolytic or cross-linking effects on different amino acids, combinations of two or more enzymes or cross-linking agents can be used.

Acellular Tissue Matrices

[0049] The methods of the present disclosure can be used to provide localized modification of properties of any tissue matrix, including the tissue matrix of cellularized tissues, partially decellularized tissue, or artificially manufactured matrices. In some embodiments, however, the tissue matrices include acellular tissue matrix. The term “acellular tissue matrix,” as used herein, refers generally to any tissue matrix that is substantially free of cells and/or cellular components.

[0050] Tissue matrices can be processed in a variety of ways, as described below to produce decellularized or partially decellularized tissues. The processing steps described below can be used along with and of (either before or after) the processes described herein for producing tissue matrices having variations mechanical and/or biological properties.

[0051] In general, the steps involved in the production of an acellular tissue matrix include harvesting the tissue from a donor (e.g., a human cadaver or animal source) and cell removal under conditions that preserve biological and structural function. In certain embodiments, the process includes chemical treatment to stabilize the tissue and avoid biochemical and structural degradation together with or before cell removal. In various embodiments, the stabilizing solution arrests and

prevents osmotic, hypoxic, autolytic, and proteolytic degradation, protects against microbial contamination, and reduces mechanical damage that can occur with tissues that contain, for example, smooth muscle components (e.g., blood vessels). The stabilizing solution may contain an appropriate buffer, one or more antioxidants, one or more oncotic agents, one or more antibiotics, one or more protease inhibitors, and/or one or more smooth muscle relaxants.

[0052] The tissue is then placed in a decellularization solution to remove viable cells (e.g., epithelial cells, endothelial cells, smooth muscle cells, and fibroblasts) from the structural matrix without damaging the biological and structural integrity of the collagen matrix. The decellularization solution may contain an appropriate buffer, salt, an antibiotic, one or more detergents (e.g., TRITON X-100™, sodium deoxycholate, polyoxyethylene (20) sorbitan mono-oleate), one or more agents to prevent cross-linking, one or more protease inhibitors, and/or one or more enzymes. In some embodiments, the decellularization solution comprises 1% TRITON X-100™ in RPMI media with Gentamicin and 25 mM EDTA (ethylenediaminetetraacetic acid). In some embodiments, the tissue is incubated in the decellularization solution overnight at 37 °C with gentle shaking at 90 rpm. In certain embodiments, additional detergents may be used to remove fat from the tissue sample. For example, in some embodiments, 2% sodium deoxycholate is added to the decellularization solution.

[0053] Skin, parts of skin (e.g., dermis), and other tissues such as blood vessels, heart valves, fascia, cartilage, bone, and nerve connective tissue may be used to create acellular matrices within the scope of the present disclosure. Acellular tissue matrices can be tested or evaluated to determine if they are substantially free of cell and/or cellular components in a number of ways. For example, processed

tissues can be inspected with light microscopy to determine if cells (live or dead) and/or cellular components remain. In addition, certain assays can be used to identify the presence of cells or cellular components. For example, DNA or other nucleic acid assays can be used to quantify remaining nuclear materials within the tissue matrices. Generally, the absence of remaining DNA or other nucleic acids will be indicative of complete decellularization (i.e., removal of cells and/or cellular components). Finally, other assays that identify cell-specific components (e.g., surface antigens) can be used to determine if the tissue matrices are acellular. Skin, parts of skin (e.g., dermis), and other tissues such as blood vessels, heart valves, fascia, cartilage, bone, and nerve connective tissue may be used to create acellular matrices within the scope of the present disclosure.

[0054] After the decellularization process, the tissue sample is washed thoroughly with saline. In some exemplary embodiments, e.g., when xenogenic material is used, the decellularized tissue is then treated overnight at room temperature with a deoxyribonuclease (DNase) solution. In some embodiments, the tissue sample is treated with a DNase solution prepared in DNase buffer (20 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), 20 mM CaCl_2 and 20 mM MgCl_2). Optionally, an antibiotic solution (e.g., Gentamicin) may be added to the DNase solution. Any suitable buffer can be used as long as the buffer provides suitable DNase activity.

[0055] While an acellular tissue matrix may be made from one or more individuals of the same species as the recipient of the acellular tissue matrix graft, this is not necessarily the case. Thus, for example, an acellular tissue matrix may be made from porcine tissue and implanted in a human patient. Species that can serve as recipients of acellular tissue matrix and donors of tissues or organs for the

production of the acellular tissue matrix include, without limitation, mammals, such as humans, nonhuman primates (e.g., monkeys, baboons, or chimpanzees), pigs, cows, horses, goats, sheep, dogs, cats, rabbits, guinea pigs, gerbils, hamsters, rats, or mice.

[0056] Elimination of the α -gal epitopes from the collagen-containing material may diminish the immune response against the collagen-containing material. The α -gal epitope is expressed in non-primate mammals and in New World monkeys (monkeys of South America) as well as on macromolecules such as proteoglycans of the extracellular components. U. Galili et al., J. Biol. Chem. 263: 17755 (1988). This epitope is absent in Old World primates (monkeys of Asia and Africa and apes) and humans, however. Id. Anti-gal antibodies are produced in humans and primates as a result of an immune response to α -gal epitope carbohydrate structures on gastrointestinal bacteria. U. Galili et al., Infect. Immun. 56: 1730 (1988); R. M. Hamadeh et al., J. Clin. Invest. 89: 1223 (1992).

[0057] Since non-primate mammals (e.g., pigs) produce α -gal epitopes, xenotransplantation of collagen-containing material from these mammals into primates often results in rejection because of primate anti-Gal binding to these epitopes on the collagen-containing material. The binding results in the destruction of the collagen-containing material by complement fixation and by antibody dependent cell cytotoxicity. U. Galili et al., Immunology Today 14: 480 (1993); M. Sandrin et al., Proc. Natl. Acad. Sci. USA 90: 11391 (1993); H. Good et al., Transplant. Proc. 24: 559 (1992); B. H. Collins et al., J. Immunol. 154: 5500 (1995). Furthermore, xenotransplantation results in major activation of the immune system to produce increased amounts of high affinity anti-gal antibodies. Accordingly, in some embodiments, when animals that produce α -gal epitopes are used as the tissue

source, the substantial elimination of α -gal epitopes from cells and from extracellular components of the collagen-containing material, and the prevention of re-expression of cellular α -gal epitopes can diminish the immune response against the collagen-containing material associated with anti-gal antibody binding to α -gal epitopes.

[0058] To remove α -gal epitopes, after washing the tissue thoroughly with saline to remove the DNase solution, the tissue sample may be subjected to one or more enzymatic treatments to remove certain immunogenic antigens, if present in the sample. In some embodiments, the tissue sample may be treated with an α -galactosidase enzyme to eliminate α -gal epitopes if present in the tissue. In some embodiments, the tissue sample is treated with α -galactosidase at a concentration of 300 U/L prepared in 100 mM phosphate buffer at pH 6.0. In other embodiments, the concentration of α -galactosidase is increased to 400 U/L for adequate removal of the α -gal epitopes from the harvested tissue. Any suitable enzyme concentration and buffer can be used as long as sufficient removal of antigens is achieved.

[0059] Alternatively, rather than treating the tissue with enzymes, animals that have been genetically modified to lack one or more antigenic epitopes may be selected as the tissue source. For example, animals (e.g., pigs) that have been genetically engineered to lack the terminal α -galactose moiety can be selected as the tissue source. For descriptions of appropriate animals see co-pending U.S. Application Serial No. 10/896,594 and U.S. Patent No. 6,166,288, the disclosures of which are incorporated herein by reference in their entirety. In addition, certain exemplary methods of processing tissues to produce acellular matrices with or without reduced amounts of or lacking alpha-1,3-galactose moieties, are described in Xu, Hui. et al., "A Porcine-Derived Acellular Dermal Scaffold that Supports Soft Tissue Regeneration: Removal of Terminal Galactose- α -(1,3)-Galactose and

Retention of Matrix Structure,” Tissue Engineering, Vol. 15, 1-13 (2009), which is incorporated by reference in its entirety.

[0060] After the acellular tissue matrix is formed, histocompatible, viable cells may optionally be seeded in the acellular tissue matrix to produce a graft that may be further remodeled by the host. In some embodiments, histocompatible viable cells may be added to the matrices by standard in vitro cell co-culturing techniques prior to transplantation, or by in vivo repopulation following transplantation. In vivo repopulation can be by the recipient's own cells migrating into the acellular tissue matrix or by infusing or injecting cells obtained from the recipient or histocompatible cells from another donor into the acellular tissue matrix in situ. Various cell types can be used, including embryonic stem cells, adult stem cells (e.g. mesenchymal stem cells), and/or neuronal cells. In various embodiments, the cells can be directly applied to the inner portion of the acellular tissue matrix just before or after implantation. In certain embodiments, the cells can be placed within the acellular tissue matrix to be implanted, and cultured prior to implantation.

WHAT IS CLAIMED IS:

1. A method for treating a tissue matrix, comprising:
selecting a collagen-containing tissue matrix; and
cross-linking select portions of the tissue matrix to produce a tissue matrix having mechanical or biological properties that vary across the tissue matrix.
2. The method of claim 1, wherein the tissue matrix is an acellular tissue matrix.
3. The method of either of claims 1 or 2, wherein the tissue matrix comprises a dermal tissue matrix.
4. The method of either of claims 1 or 2, wherein the tissue matrix is derived from a tissue selected from fascia, pericardial tissue, dura, umbilical cord tissue, placental tissue, cardiac valve tissue, ligament tissue, tendon tissue, arterial tissue, venous tissue, neural connective tissue, urinary bladder tissue, ureter tissue, and intestinal tissue.
5. The method of any one of claims 1-4, wherein cross-linking select portions of the tissue matrix comprises applying a fluid containing a cross-linking agent to the select portions.
6. The method of claim 5, wherein applying a fluid containing a cross-linking agent to the select portions comprises providing a solid surface having one or more channels configured to allow fluid to flow therethrough;
contacting the tissue matrix with the surface; and
causing fluid containing a cross-linking agent to flow through the channels.
7. The method of claim 6, wherein the one or more channels have at least one of a serpentine pattern, a web-like pattern, a circular pattern, a grid pattern, and a linear pattern.

8. The method of any one of claims 5-7, wherein the cross-linking agent comprises at least one of gluteraldehyde and 1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC).

9. A method for treating a tissue matrix, comprising:
selecting a collagen-containing tissue matrix; and
contacting select portions of the tissue matrix with a proteolytic enzyme to produce a tissue matrix having mechanical properties that vary across the tissue matrix.

10. The method of claim 9, wherein the tissue matrix is an acellular tissue matrix.

11. The method of either of claims 9 or 10, wherein the tissue matrix comprises a dermal tissue matrix.

12. The method of either of claims 9 or 10, wherein the tissue matrix is derived from a tissue selected from fascia, pericardial tissue, dura, umbilical cord tissue, placental tissue, cardiac valve tissue, ligament tissue, tendon tissue, arterial tissue, venous tissue, neural connective tissue, urinary bladder tissue, ureter tissue, and intestinal tissue.

13. The method of any one of claims 9-12, wherein contacting select portions of the tissue matrix with a proteolytic enzyme comprises applying a fluid containing a proteolytic enzyme to the select portions.

14. The method of claim 9, wherein contacting select portions of the tissue matrix with a proteolytic enzyme comprises providing a solid surface having one or more channels configured to allow fluid to flow therethrough;
contacting the tissue matrix with the surface; and
causing fluid containing the proteolytic enzyme to flow through the channels.

15. The method of claim 14, wherein the one or more channels have at least one of a serpentine pattern, a web-like pattern, a circular pattern, a grid pattern, and a linear pattern.

16. The method of any one of claims 9-15, wherein the enzyme is bromelain.

17. The method of any one of claims 9-15, wherein the enzyme is selected from bromelain, papain, ficin, actinidin, or combinations thereof.

18. The method of any one of claims 1-17, further including treating the tissue matrix to removal at least some of the cells and cellular components from the tissue matrix.

19. The method of claim 18, including removal all the cells and cellular components from the tissue matrix.

20. A tissue matrix produced according to the method of any one of claims 1-19.

21. A tissue product, comprising:
an acellular tissue matrix derived from a collagen-containing tissue, wherein the tissue matrix comprises a flexible sheet, and wherein the tissue matrix comprises select regions of cross-linked or proteolytically digested material, and wherein the mechanical or biological properties of the tissue matrix vary across the flexible sheet.

22. The product of claim 21, wherein the tissue matrix comprises a dermal tissue matrix.

23. The product of claim 21, wherein the tissue matrix is derived from a tissue selected from fascia, pericardial tissue, dura, umbilical cord tissue, placental tissue, cardiac valve tissue, ligament tissue, tendon tissue, arterial tissue, venous

tissue, neural connective tissue, urinary bladder tissue, ureter tissue, and intestinal tissue.

24. The product of any one of claims 21-23, select portions of the tissue matrix have been cross-linked by applying a fluid containing a cross-linking agent to the select portions of the tissue matrix.

25. The method of claim 24, wherein applying a fluid containing a cross-linking agent to the select portions comprises providing a solid surface having one or more channels configured to allow fluid to flow therethrough;

contacting the tissue matrix with the surface; and

causing fluid containing a cross-linking agent to flow through the channels.

26. The product of any one of claims 21-23, select portions of the tissue matrix have been proteolytically digested by applying a fluid containing a proteolytic enzyme to the select portions of the tissue matrix.

27. The method of claim 26, wherein applying a fluid containing a proteolytic enzyme to the select portions comprises providing a solid surface having one or more channels configured to allow fluid to flow therethrough;

contacting the tissue matrix with the surface; and

causing fluid containing the proteolytic enzyme to flow through the channels.

28. The device of any of claims 21-27, wherein the select portions of the tissue matrix have at least one of a serpentine pattern, a web-like pattern, a circular pattern, a grid pattern, and a linear pattern.






FIG. 1A

**FIG. 1B**

**FIG. 2**




FIG. 4




FIG. 3




FIG. 6




FIG. 5




FIG. 8




FIG. 7




FIG. 10





FIG. 9

**FIG. 11**

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-8, 24, 25(completely); 20-23, 28(partially)

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.